Four analysts have recently updated their ratings on Alignment Healthcare (NASDAQ:ALHC), showing a mix of bullish and bearish sentiments. The average 12-month price target is now $7.00, down 34.4% from previous estimates, with individual targets ranging from $4.50 to $9.00. Analysts from Stifel, Piper Sandler, Barclays, and UBS have adjusted their price targets and ratings due to changes in market conditions and company performance. Alignment Healthcare, a provider of Medicare Advantage plans, has shown impressive revenue growth of 28.63% as of December 31, 2023, but faces challenges in profitability and debt management.